Company intelligence / Profile preview

Aranda Pharma

Ownership: Private
Employees: ~49
Development stage: Preclinical

Overview

ADA‑308, the lead candidate, has shown excellent efficacy in preclinical studies for androgenetic alopecia and acne compared to current standards, with a clean safety profile. In prostate cancer models—including enzalutamide-resistant lines—ADA‑308 demonstrated potent AR inhibition and robust antitumor activity in vitro and in vivo but was discontinued for this indication before clinical trials. No clinical results are available yet as all active programs remain preclinical.

Therapeutic areas: OncologyCardiovascularDermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

ADA-308

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aranda Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aranda Pharma.

Explore the full profile